Bausch Health Companies Deferred Revenue 2011-2026 | BHC

Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.

Features of the metric

Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability.
Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages.
Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results.
Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks.
Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).

Annual Deferred Revenue Bausch Health Companies

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	-	-	-	26 M	16.6 M	18.8 M	19.5 M	7.03 M	12.8 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
26 M	7.03 M	16.8 M

Quarterly Deferred Revenue Bausch Health Companies

2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7.03 M	18.1 M	7.03 M	8.73 M	12.8 M	12.8 M	12.8 M	12.8 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
18.1 M	7.03 M	11.5 M

Deferred Revenue of other stocks in the Drug manufacturers industry

Issuer	Deferred Revenue	Price	% 24h	Market Cap	Country
Aerie Pharmaceuticals AERI	85.4 M	-	-	$ 754 M	USA
AcelRx Pharmaceuticals ACRX	49 K	-	7.5 %	$ 6.35 M	USA
Catalent CTLT	250 M	-	-	$ 11.5 B	USA
Adamis Pharmaceuticals Corporation ADMP	27.8 K	-	0.86 %	$ 117 M	USA
DURECT Corporation DRRX	545 K	-	-	$ 50.1 M	USA
Endo International plc ENDP	600 K	-	-	$ 28.9 M	Irlanda
Avadel Pharmaceuticals plc AVDL	114 K	-	-	$ 2.06 B	France
China Pharma Holdings CPHI	162 K	$ 0.55	-3.51 %	$ 9.61 M	China
Cumberland Pharmaceuticals CPIX	207 K	$ 4.58	-5.37 %	$ 64.4 M	USA
HEXO Corp. HEXO	8.21 M	-	2.45 %	$ 38.1 M	Canada
Aurora Cannabis ACB	27 M	$ 3.48	-6.2 %	$ 86.3 M	Canada
Athenex ATNX	2.82 M	-	-23.39 %	$ 1.76 M	USA
Harrow Health HROW	788 K	$ 38.6	-27.96 %	$ 1.42 B	USA
Emergent BioSolutions EBS	27.2 M	$ 8.92	-0.78 %	$ 457 M	USA
ProPhase Labs PRPH	2.5 M	-	-	$ 5.07 M	USA
Assertio Holdings ASRT	200 K	$ 11.9	1.06 %	$ 845 M	USA
Radius Health RDUS	1 M	-	-	$ 1.42 B	USA
Evolus EOLS	11.5 M	$ 4.13	-3.73 %	$ 266 M	USA
Eagle Pharmaceuticals EGRX	6 M	-	-39.89 %	$ 27.7 M	USA
Perrigo Company plc PRGO	122 M	$ 11.39	-7.89 %	$ 1.58 B	USA
Rockwell Medical RMTI	46 K	$ 0.9	-0.12 %	$ 21 M	USA
TherapeuticsMD TXMD	523 K	$ 2.22	-0.89 %	$ 23.2 M	USA
Veru VERU	400 K	$ 2.52	-3.82 %	$ 340 M	USA
cbdMD YCBD	503 K	$ 0.77	-4.37 %	$ 3.32 M	USA
Pacira BioSciences PCRX	102 K	$ 22.1	3.85 %	$ 1.02 B	USA
OptiNose OPTN	160 K	-	-	$ 1.08 B	USA
Recro Pharma REPH	543 K	-	-4.76 %	$ 65.3 M	USA
SCYNEXIS SCYX	1.19 M	$ 0.75	0.33 %	$ 35.9 M	USA
Solid Biosciences SLDB	10.4 M	$ 5.96	-3.87 %	$ 243 M	USA
Sonoma Pharmaceuticals SNOA	641 K	$ 2.75	-3.17 %	$ 3.41 M	USA
Tilray TLRY	23.7 M	$ 7.36	-3.16 %	$ 4.55 B	Canada
Zynerba Pharmaceuticals ZYNE	172 K	-	-	$ 55.5 M	USA